Valneva, Pfizer push back timeline for Lyme disease vaccine

Pfizer and its partner Valneva, a France-based vaccine maker, have pushed back when they expect to submit an approval application for their experimental Lyme disease shot from 2025 to 2026, according to an earnings statement Thursday.